Suppr超能文献

糖尿病与缺血性脑卒中的长期结局:来自 Get With The Guidelines-Stroke 的研究结果。

Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke.

机构信息

Brigham and Women's Hospital (Department of Medicine) and Harvard Medical School, 75 Francis Street, Boston, MA, USA.

Department of Biostatistics and Bioinformatics, Duke University, 2424 Erwin Road, Hock Plaza Suite 1102, Durham, NC, USA.

出版信息

Eur Heart J. 2018 Jul 1;39(25):2376-2386. doi: 10.1093/eurheartj/ehy036.

Abstract

AIMS

There is a paucity of data on the influence of diabetes on long-term outcomes after ischaemic stroke (IS). We assessed whether outcomes after IS differ between patients with and without diabetes.

METHODS AND RESULTS

Patients aged ≥65 years (n = 409 060) in Get With The Guidelines-Stroke (nationwide registry of stroke patients from 1690 sites in the USA) were followed for 3 years post-discharge. The outcomes of interest were mortality, cardiovascular and non-cardiovascular hospitalizations, heart failure (HF), and recurrence of IS/transient ischaemic attack (TIA). Patients with diabetes (29.6%) were younger and had more comorbidities. At 3 years post-discharge after IS, diabetes was associated with higher risks of adverse outcomes: all-cause mortality [cumulative incidence 46.0% vs. 44.2%, absolute difference (AD) 1.8%; adjusted hazard ratio (aHR) 1.24, 95% confidence interval 1.23-1.25], all-cause readmission (71.3% vs. 63.7%, AD 7.6%; aHR 1.22, 1.21-1.23), composite of mortality and all-cause readmission (84.1% vs. 79.3%, AD 4.8%; aHR 1.21, 1.20-1.22), composite of mortality and cardiovascular readmission (69.5% vs. 64.3%, AD 5.2%; aHR 1.19, 1.18-1.20), IS/TIA readmission (15.9% vs. 13.3%, AD 2.6%; aHR 1.18, 1.16-1.20), HF readmission (10.3% vs. 6.4%, AD 3.9%; aHR 1.60, 1.56-1.64), non-cardiovascular readmission (58.3% vs. 50.3%, AD 8.0%; aHR 1.28, 1.26-1.29), and non-IS/TIA readmission (67.6% vs. 59.7%, AD 7.9%; aHR 1.23, 1.22-1.25). Accounting for the initial severity of stroke using the National Institute of Health Stroke Scale as well as using propensity score matching method as a sensitivity analysis, did not modify the results.

CONCLUSION

Among older IS patients diabetes was associated with increased risks of death, cardiovascular and non-cardiovascular hospitalizations, HF, and IS/TIA recurrence.

摘要

目的

关于糖尿病对缺血性脑卒中(IS)后长期预后的影响的数据较少。我们评估了 IS 患者中有无糖尿病对预后的影响是否不同。

方法和结果

在 Get With The Guidelines-Stroke(美国 1690 个地点的卒中患者的全国登记处)中,年龄≥65 岁(n=409060)的患者在出院后 3 年内进行随访。主要结局为死亡率、心血管和非心血管住院、心力衰竭(HF)和再发 IS/TIA。合并糖尿病(29.6%)的患者更年轻,且合并症更多。IS 后 3 年,糖尿病与更高的不良结局风险相关:全因死亡率[累积发生率 46.0% vs. 44.2%,绝对差值(AD)1.8%;调整后风险比(aHR)1.24,95%置信区间(CI)1.23-1.25]、全因再入院(71.3% vs. 63.7%,AD 7.6%;aHR 1.22,1.21-1.23)、全因死亡和再入院的复合终点(84.1% vs. 79.3%,AD 4.8%;aHR 1.21,1.20-1.22)、全因死亡和心血管再入院的复合终点(69.5% vs. 64.3%,AD 5.2%;aHR 1.19,1.18-1.20)、IS/TIA 再入院(15.9% vs. 13.3%,AD 2.6%;aHR 1.18,1.16-1.20)、HF 再入院(10.3% vs. 6.4%,AD 3.9%;aHR 1.60,1.56-1.64)、非心血管再入院(58.3% vs. 50.3%,AD 8.0%;aHR 1.28,1.26-1.29)和非 IS/TIA 再入院(67.6% vs. 59.7%,AD 7.9%;aHR 1.23,1.22-1.25)。使用国立卫生研究院卒中量表(National Institute of Health Stroke Scale)作为初始卒中严重程度的指标,以及使用倾向评分匹配法作为敏感性分析,结果均未改变。

结论

在老年 IS 患者中,糖尿病与死亡、心血管和非心血管住院、HF 以及 IS/TIA 复发的风险增加相关。

相似文献

引用本文的文献

9
Metabolic Syndrome in Non-diabetic Stroke Patients.非糖尿病性中风患者的代谢综合征
Cureus. 2024 Nov 4;16(11):e72972. doi: 10.7759/cureus.72972. eCollection 2024 Nov.

本文引用的文献

4
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
5
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
7
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.缺血性中风或短暂性脑缺血发作后的吡格列酮
N Engl J Med. 2016 Apr 7;374(14):1321-31. doi: 10.1056/NEJMoa1506930. Epub 2016 Feb 17.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验